Prediction of Residual Disease After Primary Cytoreductive Surgery for Advanced-Stage Ovarian Cancer Accuracy of Clinical Judgment

Gerestein, C.G.; Spek, Dirkina W. van der; Eijkemans, Marinus J.C.; Bakker, Jeanette; Kooi, G.S.; Burger, Curt W.

doi:10.1111/igc.0b013e3181bf82be

Cited by 8 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[9][10][11] For optimal CRS in patients with advanced stage cancer, clinicians will usually remove the primary ovary, together with the whole uterus, double attachments, pelvic metastasis nodules, and even part of the bowel if metastasis is diagnosed. [12,13] Despite this significant resection, most patients with advanced EOC do not in Abdominal miliary spread and metastasis is one of the most aggressive features in advanced ovarian cancer patients. The current standard treatment of advanced ovarian cancer is cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC).…”

Section: Introductionmentioning

confidence: 99%

“…The current standard treatment of advanced stage EOC consists of cytoreductive surgery (CRS) and platinum‐based (e.g., cisplatin) chemotherapies . For optimal CRS in patients with advanced stage cancer, clinicians will usually remove the primary ovary, together with the whole uterus, double attachments, pelvic metastasis nodules, and even part of the bowel if metastasis is diagnosed . Despite this significant resection, most patients with advanced EOC do not in practice receive optimal CRS outcomes due to the extreme difficulty of completely excising all microtumors less than 1 cm during operation, which typically exhibit numerous miliary nodules diffused in the peritoneum, intestinal canal, and abdominal viscera .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intraoperative Raman‐Guided Chemo‐Photothermal Synergistic Therapy of Advanced Disseminated Ovarian Cancers

Zhang

Liu

Thackray

et al. 2018

Small

View full text Add to dashboard Cite

Abdominal miliary spread and metastasis is one of the most aggressive features in advanced ovarian cancer patients. The current standard treatment of advanced ovarian cancer is cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). However, most patients cannot receive optimal CRS outcomes due to the extreme difficulty of completely excising all microtumors during operation. Though HIPEC can improve prognosis, treatment is untargeted and may damage healthy organs and cause complications. New strategies for precise detection and complete elimination of disseminated microtumors without side effects are therefore highly desirable. Here, cisplatin-loaded gap-enhanced Raman tags (C-GERTs) are designed specifically for the intraoperative detection and elimination of unresectable disseminated advanced ovarian tumors. With unique and strong Raman signals, good biocompatibility, decent plasmonic photothermal conversion, and good drug loading capacity, C-GERTs enable detection and specific elimination of microtumors with a minimum diameter of 1 mm via chemo-photothermal synergistic therapy, causing minimal side effects and significantly prolonging survival in mice. The results demonstrate that C-GERTs-based chemo-photothermal synergistic therapy can effectively control the spread of disseminated tumors in mice and has potential as a safe and powerful method for treatment of advanced ovarian cancers, to improve survival and life quality of patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Intraoperative Raman‐Guided Chemo‐Photothermal Synergistic Therapy of Advanced Disseminated Ovarian Cancers

Zhang

Liu

Thackray

et al. 2018

Small

View full text Add to dashboard Cite

show abstract

“…The prediction to achieve a complete cytoreductive surgery is most often based on imaging techniques, predominantly CT scans, but this seems to be an inaccurate method to establish the resectability of ovarian cancer [72][73][74] . Specific disease details, such as miliary spread, and the extent of intra-abdominal disease could be well established by diagnostic laparoscopy prior to cytoreductive surgery.…”

Section: Part Iii: Optimising Patient Selection For Primary Surgery Omentioning

confidence: 99%

Optimising patient selection to improve outcome in advanced ovarian cancer

Timmermans¹

View full text Add to dashboard Cite

People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website. • The final author version and the galley proof are versions of the publication after peer review. • The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal. If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

show abstract

Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer

Rutten¹,

Leeflang²,

Kenter³

et al. 2012

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Prediction of Residual Disease After Primary Cytoreductive Surgery for Advanced-Stage Ovarian Cancer Accuracy of Clinical Judgment

Abstract: Clinical judgment of residual disease after primary cytoreductive surgery in patients with advanced-stage EOC shows limited accuracy. Given the poor interobserver reproducibility, prediction models could attribute to uniform treatment decisions and improve counseling.

Cited by 8 publications

References 24 publications

Intraoperative Raman‐Guided Chemo‐Photothermal Synergistic Therapy of Advanced Disseminated Ovarian Cancers

Intraoperative Raman‐Guided Chemo‐Photothermal Synergistic Therapy of Advanced Disseminated Ovarian Cancers

Optimising patient selection to improve outcome in advanced ovarian cancer

Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer

Contact Info

Product

Resources

About